Among these, the core therapeutic targets closely related to the development and progression of RA are AKT1, TLR4, EGFR, TNF, TP53, NFKB1, JAK2, BCL2, MAPK1, and SYK. This evidence concerns the gene BCL2 and rheumatoid arthritis.